Strong core operations battling an ongoing legal shadow
- Sotera's core strength is Sterigenics plus Nordion, a rare mix of sterilization plants and Cobalt-60 supply.
- Q2 2026 total revenue reached $321 million, up 9.2% year over year with raised guidance.
- Nelson Labs returned to growth in Q2 2026, posting a 6.3% revenue increase under new leadership.
- Ethylene oxide lawsuits remain the main risk, with a key trial in California scheduled for early 2027.
- New CEO Alton Shader is pushing cross-selling and preparing for revenue from a new X-ray facility in Q3.
Good business, hard overhang
Sotera sits in a needed part of healthcare. Many medical devices and drug products must be sterilized before use. Customers do not pick these services lightly, because failure can stop product shipments or create safety issues.
The bull case starts with the link between Sterigenics and Nordion. Sterigenics runs sterilization services. Nordion supplies Cobalt-60, the isotope used in gamma sterilization. That gives Sotera more control over a key input than many rivals have, and Q2 2026 showed pricing power in the main sterilization business.
The bear case is not small. Ethylene oxide, or EO, is a gas used to sterilize products that cannot handle heat or radiation. It has also created a long legal fight over emissions. While the New Mexico litigation was settled for an immaterial amount, the bigger open questions are the remaining Georgia claims and a California trial slated for early 2027.
The leadership change matters. Alton Shader became CEO effective May 26, 2026. The second half of 2026 should show whether new leadership can keep Nelson Labs growing, push X-ray and other alternatives forward, and reduce the legal cloud.
Paid to make products usable
Sotera makes money by doing work that healthcare companies often cannot skip. A medical device maker may need sterilization, lab testing, and expert advice before a product reaches hospitals. Sotera charges for those services across a product's life, from development through shipping.
Sterigenics is the largest piece. It uses gamma irradiation, EO processing, and E-beam irradiation to sterilize medical devices, drugs, and some food safety products. This business can be sticky because customers must validate their process, which means prove that a specific plant and method works for their product.
Nordion is the supply backbone for gamma sterilization. It sells Cobalt-60 and gamma systems, and it helps support Sterigenics' position. Nelson Labs is different. It provides microbiology, chemistry testing, and advisory work.
The model breaks if legal costs or new rules eat the cash that the core business produces. Sotera generated positive operating cash flow recently, but that does not remove the risk of more settlements or higher environmental spending.
Sterilization, supply, and testing
Sterigenics gamma sterilization
Gamma sterilization uses radiation to sterilize large batches of products. It is helped by Sotera's Nordion supply link.
Sterigenics EO processing
EO can sterilize products that may not work well with heat or some forms of radiation. It is useful, but it is also the center of Sotera's largest legal and regulatory risk.
E-beam and X-ray sterilization
E-beam is already part of the service mix, while a new X-ray facility begins generating revenue in Q3 2026. These methods could help reduce long-term dependence on EO.
Nordion Cobalt-60 supply
Nordion supplies Cobalt-60, a key input for gamma sterilization, and sells gamma irradiation systems. Q2 2026 revenue rose 15.8%, helped by Co-60 harvest timing.
Nelson Labs testing and advisory
Nelson Labs tests products and gives technical advice to medical device and pharma customers. It returned to growth in Q2 2026 with a 6.3% revenue increase.
NO2-based sterilization investment
Sotera is investing in nitrogen dioxide based sterilization technology. This is an option on future demand for alternatives to EO.
Q2 mix still favors sterilization
Segment shares use Q2 2026 net revenues: Sterigenics $212 million, Nordion $49 million, and Nelson Labs $61 million. The mix can move quarter to quarter because Nordion revenue depends partly on Co-60 harvest timing.
What could go wrong
EO litigation keeps draining cash
High impact · High oddsEO lawsuits are the main risk to the stock story. Sotera settled New Mexico claims for an immaterial amount, but the Georgia appellate process remains unresolved and a California trial is expected in early 2027.
Nelson Labs recovery is fragile
Medium impact · Medium oddsNelson Labs saw revenue grow 6.3% in Q2 2026 under new President Riaz Bandali. If this recovery stalls, it weakens the case that Sotera can grow beyond core sterilization.
EPA rules force more spending
High impact · Medium oddsEO is useful but closely watched by regulators. The company already expected environmental facility enhancements to be a large capital use. If the EPA or local regulators tighten rules again, Sotera may need to spend more than planned.
Alternative sterilization adoption takes time
Medium impact · Medium oddsX-ray, E-beam, and NO2 could reduce some long-term EO risk. The new X-ray facility begins generating revenue in Q3 2026, but customers must test and approve new sterilization methods for each product.
Nordion timing looks better than demand
Medium impact · Medium oddsNordion had 15.8% Q2 2026 revenue growth, but the company noted a major driver was favorable Co-60 harvest schedule timing. That can make a quarter look stronger than the base trend.
In one breath
What does Sotera Health do?
Sotera helps healthcare companies sterilize products, source Cobalt-60 for gamma sterilization, and test medical products in labs. Its main customers are medical device, pharmaceutical, and related healthcare companies.
Why is ethylene oxide important to Sotera?
Ethylene oxide, or EO, is a sterilization gas used for products that may not work with other methods. It is also the source of major lawsuits and regulatory risk for Sotera.
Why did Sotera change CEOs in 2026?
The company named Alton Shader as CEO effective May 26, 2026, with Michael Petras moving to Executive Chairman. The key investor question is whether the new CEO changes capital allocation, fixes Nelson Labs, and speeds the shift to alternative sterilization.
Is Sotera mostly a lab testing company?
No. Nelson Labs is meaningful, but Sterigenics is the largest segment by Q2 2026 revenue. The main investment debate is still about sterilization strength versus EO legal risk.
